Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aerovate Therapeutics Inc (NQ: AVTE ) 2.600 +0.410 (+18.72%) Streaming Delayed Price Updated: 1:23 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aerovate Therapeutics Inc AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders Today 9:43 EDT From Halper Sadeh LLC Via Business Wire Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders Today 9:31 EDT From Ademi LLP Via Business Wire Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement Today 7:00 EDT From Jade Biosciences Via GlobeNewswire Aerovate Therapeutics to Explore Strategic Alternatives July 08, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension June 17, 2024 AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference May 21, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights May 13, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference March 27, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights March 25, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair March 06, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension November 20, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights November 13, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights August 14, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors July 11, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference June 01, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference May 22, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights May 15, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights March 29, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference March 02, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors January 23, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research November 17, 2022 Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Third Quarter 2022 Financial Results November 14, 2022 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022 October 18, 2022 Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor From Aerovate Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
